The French pharmaceutical technology company Aqemia has entered into a $140 million research collaboration agreement with global pharmaceutical giant Sanofi, aiming to accelerate the discovery of innovative drugs using AI. AQEMIA will utilize its unique platform combined with AI to identify the correct chemical molecules for therapeutic targets of interest to Sanofi on a large scale. This partnership will cover the entire drug discovery process, with Sanofi leveraging its global research and development expertise to expedite the development of therapeutic drugs for unmet medical needs. The collaboration agreement also stipulates that AQEMIA can earn up to $140 million in revenue upon successful completion of research and development milestones.